|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Flegal KM, Carroll MD, Kit BK and Ogden
CL: Prevalence of obesity and trends in the distribution of body
mass index among US adults, 1999–2010. JAMA. 307:491–497. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
De Pergola G and Silvestris F: Obesity as
a major risk factor for cancer. J Obes. 2013:2915462013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
O'Doherty MG, Freedman ND, Hollenbeck AR,
Schatzkin A and Abnet CC: A prospective cohort study of obesity and
risk of oesophageal and gastric adenocarcinoma in the NIH-AARP diet
and health study. Gut. 61:1261–1268. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nieman KM, Romero IL, Van Houten B and
Lengyel E: Adipose tissue and adipocytes support tumorigenesis and
metastasis. Biochim Biophys Acta. 1831:1533–1541. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee CH, Woo YC, Wang Y, Yeung CY, Xu A and
Lam KS: Obesity, adipokines and cancer: An update. Clin Endocrinol
(Oxf). 83:147–156. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Galli M, Van Gool F, Rongvaux A, Andris F
and Leo O: The nicotinamide phosphoribosyltransferase: A molecular
link between metabolism, inflammation, and cancer. Cancer Res.
70:8–11. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Revollo JR, Grimm AA and Imai S: The
regulation of nicotinamide adenine dinucleotide biosynthesis by
Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol.
23:164–170. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bi TQ and Che XM: Nampt/PBEF/visfatin and
cancer. Cancer Biol Ther. 10:119–125. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bi TQ, Che XM, Liao XH, Zhang DJ, Long HL,
Li HJ and Zhao W: Overexpression of Nampt in gastric cancer and
chemopotentiating effects of the Nampt inhibitor FK866 in
combination with fluorouracil. Oncol Rep. 26:1251–1257.
2011.PubMed/NCBI
|
|
11
|
Bosch-Presegué L and Vaquero A: The dual
role of sirtuins in cancer. Genes Cancer. 2:648–662. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Asaka R, Miyamoto T, Yamada Y, Ando H,
Mvunta DH, Kobara H and Shiozawa T: Sirtuin 1 promotes the growth
and cisplatin resistance of endometrial carcinoma cells: A novel
therapeutic target. Lab Invest. 95:1363–1373. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin Z and Fang D: The roles of SIRT1 in
cancer. Genes Cancer. 4:97–104. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vellinga TT, Borovski T, de Boer VC,
Fatrai S, van Schelven S, Trumpi K, Verheem A, Snoeren N, Emmink
BL, Koster J, et al: SIRT1/PGC1α-dependent increase in oxidative
phosphorylation supports chemotherapy resistance of colon cancer.
Clin Cancer Res. 21:2870–2879. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Derr RS, van Hoesel AQ, Benard A,
Goossens-Beumer IJ, Sajet A, Dekker-Ensink NG, de Kruijf EM,
Bastiaannet E, Smit VT, van de Velde CJ and Kuppen PJ: High nuclear
expression levels of histone-modifying enzymes LSD1, HDAC2 and
SIRT1 in tumor cells correlate with decreased survival and
increased relapse in breast cancer patients. BMC Cancer.
14:6042014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang L, Wang X and Chen P: MiR-204 down
regulates SIRT1 and reverts SIRT1-induced epithelial-mesenchymal
transition, anoikis resistance and invasion in gastric cancer
cells. BMC Cancer. 13:2902013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen WY, Wang DH, Yen RC, Luo J, Gu W and
Baylin SB: Tumor suppressor HIC1 directly regulates SIRT1 to
modulate p53-dependent DNA-damage responses. Cell. 123:437–448.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lim CS: Human SIRT1: A potential biomarker
for tumorigenesis? Cell Biol Int. 31:636–637. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Santucci M, Vignudelli T, Ferrari S, Mor
M, Scalvini L, Bolognesi ML, Uliassi E and Costi MP: The hippo
pathway and YAP/TAZ-TEAD protein-protein interaction as targets for
regenerative medicine and cancer treatment. J Med Chem.
58:4857–4873. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Orr BA, Bai H, Odia Y, Jain D, Anders RA
and Eberhart CG: Yes-associated protein 1 is widely expressed in
human brain tumors and promotes glioblastoma growth. J Neuropathol
Exp Neurol. 70:568–577. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chan SW, Lim CJ, Chen L, Chong YF, Huang
C, Song H and Hong W: The Hippo pathway in biological control and
cancer development. J Cell Physiol. 226:928–939. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Moroishi T, Hansen CG and Guan KL: The
emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 15:73–79.
2015. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mo JS, Park HW and Guan KL: The Hippo
signaling pathway in stem cell biology and cancer. EMBO Rep.
15:642–656. 2014.PubMed/NCBI
|
|
24
|
Johnson R and Halder G: The two faces of
Hippo: Targeting the Hippo pathway for regenerative medicine and
cancer treatment. Nat Rev Drug Discov. 13:63–79. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hata S, Hirayama J, Kajiho H, Nakagawa K,
Hata Y, Katada T, Furutani-Seiki M and Nishina H: A novel
acetylation cycle of transcription co-activator Yes-associated
protein that is downstream of Hippo pathway is triggered in
response to SN2 alkylating agents. J Biol Chem. 287:22089–22098.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang J, Tang X, Weng W, Qiao Y, Lin J, Liu
W, Liu R, Ma L, Yu W, Yu Y, et al: The membrane protein melanoma
cell adhesion molecule (MCAM) is a novel tumor marker that
stimulates tumorigenesis in hepatocellular carcinoma. Oncogene.
34:5781–5795. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mao B, Hu F, Cheng J, Wang P, Xu M, Yuan
F, Meng S, Wang Y, Yuan Z and Bi W: SIRT1 regulates YAP2-mediated
cell proliferation and chemoresistance in hepatocellular carcinoma.
Oncogene. 33:1468–1474. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li HJ, Che XM, Zhao W, He SC, Zhang ZL and
Chen R: Diet-induced obesity potentiates the growth of gastric
cancer in mice. Exp Ther Med. 4:615–620. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qian SS, Gao J, Wang JX, Liu Y and Dong
HY: Establishment of a mouse forestomach carcinoma cell line (MFC)
with spontaneous hematogenous metastasis and preliminary study of
its biological characteristics. Zhonghua Zhong Liu Za Zhi.
9:261–264. 1987.(In Chinese). PubMed/NCBI
|
|
30
|
Yakar S, Nunez NP, Pennisi P, Brodt P, Sun
H, Fallavollita L, Zhao H, Scavo L, Novosyadlyy R, Kurshan N, et
al: Increased tumor growth in mice with diet-induced obesity:
Impact of ovarian hormones. Endocrinology. 147:5826–5834. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li HJ, Che XM, Zhao W, He SC, Zhang ZL,
Chen R, Fan L and Jia ZL: Diet-induced obesity promotes murine
gastric cancer growth through a nampt/sirt1/c-myc positive feedback
loop. Oncol Rep. 30:2153–2160. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Deng T, Lyon CJ, Bergin S, Caligiuri MA
and Hsueh WA: Obesity, Inflammation, and Cancer. Annu Rev Pathol.
11:421–449. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Garten A, Petzold S, Körner A, Imai S and
Kiess W: Nampt: Linking NAD biology, metabolism and cancer. Trends
Endocrinol Metab. 20:130–138. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pilz S, Mangge H, Obermayer-Pietsch B and
Marz W: Visfatin/pre-B-cell colony-enhancing factor: A protein with
various suggested functions. J Endocrinol Invest. 30:138–144. 2007.
View Article : Google Scholar : PubMed/NCBI
|
